Evidence map›Paper›PMID 39051686›Full record

Trial reportTechnology in cancer research & treatment

Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study).

Yingying Xu, Yuehong Kong, Yifu Ma, Meiling Xu, Jiabao Yang, Junjun Zhang, Rongzheng Chen, Guangqiang Chen, Zhihui Hong, Xiangrong Zhao and 4 more

Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yingying XuCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Yuehong KongCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Yifu MaCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Meiling XuCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Jiabao YangCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Junjun ZhangCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Rongzheng ChenCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Guangqiang ChenDepartment of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Zhihui HongDepartment of Nuclear Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Xiangrong ZhaoCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Chenyang ZhangCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Pengfei XingCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Liyuan ZhangCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Peifeng ZhaoCenter for Cancer Diagnosis and Treatment, The Second Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0009-0002-0098-8154

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AscitesImmune Checkpoint InhibitorsInfusions, ParenteralNeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedPeritoneal NeoplasmsProgrammed Cell Death 1 ReceptorProspective StudiesTreatment OutcomeImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorcancerous ascitesGM-CSFhypofractionated radiotherapyimmunotherapyintraperitoneal infusion of PD-1 inhibitor

Identifiers

PMID39051686
PMCPMC11273709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.